The SYSCID consortium aims to develop a systems medicine approach for predictions in chronic inflammatory diseases (CID). The overall goal is to create a prediction framework for disease outcome to guide therapy decisions on an individual patient level enabling the choice of the right therapy at the right time. Furthermore, the SYSCID consortium targets new therapy approaches by “reprogramming” disease through epigenome editing.
Taking on this mission, SYSCID pursues the following strategic goals:
- To identify shared and unique "core disease signatures” of the CIDs inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and systemic lupus, which are associated with the disease state and independent of temporal variation to help fast and unequivocal diagnosis
- To understand mechanisms of response/non-response to specific treatments using multidimensional, dynamic molecular data from CID patients
- To generate predictive models of disease outcome to guide therapy decisions on an individual patient basis
- To foster the development of solid biomarkers and models as stratification in future long-term clinical trials
- To investigate new causative therapies by editing the epigenome code in specific immune cells